Currents in contemporary ethics

Journal of Law, Medicine and Ethics

Volumn 30, Issue 1, 2002, Pages 105-108

  Rothstein, Mark A ^a,b  

^a Herbert F Boehl Chair Law and Med   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENTIALITY; CONSULTATION; DATA BASE; HEALTH HAZARD; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL RECORD; REVIEW; SAMPLE; ACCESS TO INFORMATION; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL PROTOCOL; COMMERCIAL PHENOMENA; DUTY TO RECONTACT; ECONOMICS; GENETIC PRIVACY; HEALTH CARE FACILITY; HEALTH INSURANCE; PROFESSIONAL STANDARD; RESEARCH; STANDARD; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

ACCESS TO INFORMATION; BIOLOGICAL SPECIMEN BANKS; CLINICAL PROTOCOLS; COMMERCE; CONFIDENTIALITY; DUTY TO RECONTACT; ETHICS COMMITTEES, RESEARCH; GENETIC PRIVACY; HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT; HUMANS; INFORMED CONSENT; MEDICAL RECORD LINKAGE; PROFESSIONAL ROLE; RESEARCH; UNITED STATES;

EID: 0036516043     PISSN: 10731105     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1748-720x.2002.tb00726.x     Document Type: Review

References (15)

1. See, e.g., H.T. Greely, "Breaking the Stalemate: A Prospective Regulatory Framework for Unforeseen Research Uses of Human Tissue Samples and Health Information," Wake Forest Law Review, 34 (1999): 737-66; B.M. Knoppers, M. Hirtle, and K.C. Glass, "Commercialization of Genetic Research and Public Policy," Science, 286 (1999): 2277-78.
2. See, e.g., H.T. Greely, "Breaking the Stalemate: A Prospective Regulatory Framework for Unforeseen Research Uses of Human Tissue Samples and Health Information," Wake Forest Law Review, 34 (1999): 737-66; B.M. Knoppers, M. Hirtle, and K.C. Glass, "Commercialization of Genetic Research and Public Policy," Science, 286 (1999): 2277-78.
3. 42 U.S.C. §§ 300gg - 300gg-2 (2000).
4. 45 C.F.R. § 164.501 (protected health information) (2001).
5. 45 C.F.R. § 160.203(b) (2001).
6. 45 C.F.R. § 164.508 (2001).
7. 45 C.F.R. § 164.508(c) (2001).
8. 45 C.F.R. § 164.512(i) (2001).
9. National Bioethics Advisory Commission (NBAC), Research Involving Human Biological Materials: Ethical Issues and Policy Guidance, vol. 1 (Rockville, Maryland: U.S. Gov't Printing Office, 1999): at 64-65.
10. Id. at 64 (Recommendation 7).
11. See American Medical Association, "Section 8.031, Conflicts of Interest: Biomedical Research," Code of Medical Ethics (Chicago: American Medical Association, 2000-2001).
12. See NBAC, supra note 8, at 64-66 (Recommendation 9). See generally Greely, supra note 1.
13. See E.T. Juengst, "Commentary: What 'Community Review' Can and Cannot Do," Journal of Law, Medicine & Ethics, 28 (2000): 52-66; R.S. Sharp and M.W. Foster, "Involving Study Populations in the Review of Genetic Research," Journal of Law, Medicine & Ethics, 28 (2000): 41-51.
14. See E.T. Juengst, "Commentary: What 'Community Review' Can and Cannot Do," Journal of Law, Medicine & Ethics, 28 (2000): 52-66; R.S. Sharp and M.W. Foster, "Involving Study Populations in the Review of Genetic Research," Journal of Law, Medicine & Ethics, 28 (2000): 41-51.
15. See, e.g., Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990).